Prof. Mojisola Adeyeye, the Director General of the National Agency for Food and Drug Administration and Control (NAFDAC), has reaffirmed the Agency’s commitment to ensuring the quality, safety, and efficacy of generic medicines in Nigeria by enforcing stringent bioequivalence.
Speaking on Thursday in Lagos, Prof. Adeyeye, said that NAFDAC initiative, aimed at boosting public confidence in generic drugs, sought to prevent the circulation of substandard medications and ensure that generics provide comparable therapeutic effects to their branded counterparts.
Bioequivalence studies are vital scientific assessments that confirm the interchangeability of generic medicines with their innovator counterparts.
These studies guarantee that generic drugs deliver similar clinical outcomes, ensuring their effectiveness in managing health conditions
She said, “By mandating bioequivalence studies, NAFDAC is strengthening its regulatory framework to safeguard public health.
“This measure not only enhances trust in the pharmaceutical industry but also encourages rational prescribing practices.”
Adeyeye said that to align stakeholders and facilitate compliance, NAFDAC had outlined a strategic roadmap that included issuing comprehensive regulations and guidelines to the pharmaceutical industry.
